Table 2.

Cardiovascular Clinical End Points.

End Point	Low-Dose Methotrexate (N = 2391)		Placebo (N = 2395)		Hazard Ratio (95% CI)*	P Value
	no. of patients	incidence rate/100 person-yr	no. of patients	incidence rate/100 person-yr
Primary end points†
Final primary end point: major adverse cardio- vascular event or hospitalization for unstable angina that led to urgent revascularization	201	4.13	207	4.31	0.96 (0.79–1.16)	0.67
Original primary end point: major adverse cardiovascular event	170	3.46	167	3.43	1.01 (0.82–1.25)	0.91
Secondary end points†
Death from any cause	96	1.80	83	1.55	1.16 (0.87–1.56)
Major adverse cardiovascular event or any coronary revascularization	278	5.86	288	6.15	0.95 (0.81–1.12)
Hospitalization for congestive heart failure	48	0.95	53	1.06	0.89 (0.60–1.31)
Major adverse cardiovascular event, coronary revascularization, hospitalization for congestive heart failure, or death from any cause	344	7.30	345	7.42	0.98 (0.84–1.14)
Tertiary end points
Nonfatal myocardial infarction	113	2.29	114	2.32	0.99 (0.76–1.29)
Nonfatal stroke	28	0.55	30	0.60	0.91 (0.54–1.52)
Cardiovascular death	49	0.92	43	0.80	1.14 (0.76–1.72)
Hospitalization for unstable angina that led to urgent revascularization	41	0.81	50	1.01	0.81 (0.53–1.22)
Coronary revascularization	190	3.95	205	4.30	0.92 (0.75–1.12)
Arterial revascularization	195	4.05	185	3.84	1.05 (0.86–1.28)

^*Confidence intervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproducible.

^†Major adverse cardiovascular events included nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death.